{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAS-102+tablets", "query": { "intervention": "TAS-102 tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAS-102+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T01:47:59.357Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04393298", "title": "A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ginisortamab", "type": "DRUG" }, { "name": "trifluridine/tipiracil", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2020-07-09", "completion_date": "2024-04-11", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 3, "location_summary": "Los Angeles, California • Charleston, South Carolina • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04393298" }, { "nct_id": "NCT04776148", "title": "Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "DRUG" }, { "name": "lenvatinib", "type": "DRUG" }, { "name": "regorafenib", "type": "DRUG" }, { "name": "TAS-102 (trifluridine and tipiracil)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 563, "start_date": "2021-03-29", "completion_date": "2024-09-27", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 12, "location_summary": "Monterey, California • Marietta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Monterey", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04776148" }, { "nct_id": "NCT02500043", "title": "Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Refractory Metastatic Gastric Cancer" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 507, "start_date": "2016-02-24", "completion_date": "2019-12-19", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 24, "location_summary": "Gilbert, Arizona • Berkeley, California • Fullerton, California + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500043" }, { "nct_id": "NCT01607957", "title": "Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2012-06-17", "completion_date": "2016-05-23", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 23, "location_summary": "Glendale, Arizona • Fresno, California • Gilroy, California + 18 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01607957" }, { "nct_id": "NCT05719558", "title": "A Study of ASP1002 in Adults for Treatment of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1002", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine-Tipiracil", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2023-03-13", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 15, "location_summary": "New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Plainville", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05719558" }, { "nct_id": "NCT02031055", "title": "Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "TAS-102 with a light tracer dose of [14C]FTD", "type": "DRUG" }, { "name": "TAS-102 with a light tracer dose of [14C] TPI", "type": "DRUG" }, { "name": "TAS-102 tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-02", "completion_date": "2015-06-17", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02031055" }, { "nct_id": "NCT04073615", "title": "A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Rivoceranib", "type": "DRUG" }, { "name": "Trifluridine/Tipiracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-11-18", "completion_date": "2023-05-31", "has_results": false, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 4, "location_summary": "Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04073615" }, { "nct_id": "NCT05731947", "title": "Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Solid Tumors" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syndax Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-04-04", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Manhattan, New York + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Manhattan", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05731947" }, { "nct_id": "NCT01874522", "title": "Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors (Excluding Breast Cancer)" ], "interventions": [ { "name": "TAS-102 tablets", "type": "DRUG" }, { "name": "TAS-102 oral solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2013-07", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874522" }, { "nct_id": "NCT05029882", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Solid Tumors", "Gastroesophageal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Trifluridine/Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2021-10-13", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-05T01:47:59.357Z", "location_count": 18, "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05029882" } ] }